The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.
Study Type
OBSERVATIONAL
Enrollment
2,015
Frequency distribution of persistent and non-persistent patients across study cohorts
Time frame: 12 months
Frequency distribution of switchers, re-starters and discontinuing patients as well as patients commencing add-on therapy across the study cohorts
Time frame: 12 months
Time to discontinuation of each cohort
Time frame: 12 months
Age and sex: Townsend Score of social deprivation, time since first THIN diagnosis of glaucoma or ocular hypertension
Time frame: 12 months
Procedures: Laser, Trabeculectomy, viscocanalostomy, deep sclerectomy
Time frame: 12 months
Ocular Pharmacological Treatments: Beta-blockers and Alpha-agonists
Time frame: 12 months
Prostaglandin mono-therapies
Time frame: 12 months
The cohort of patients which were evaluated in this study were investigated for the presence of history of disease for asthma, cardiovascular disease, diabetes, renal failure and systemic hypertension. The number of patients in each cohort were
Time frame: 12 months
presented who had had (i) a 12 month history of any of the diseases or (ii) had had a history of any of the diseases.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.